Current perspectives on therapeutic antibodies

Soomin Yoon, Yong Sung Kim, Hyunbo Shim, Junho Chung

Research output: Contribution to journalReview articleResearchpeer-review

14 Citations (Scopus)

Abstract

Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.

Original languageEnglish
Pages (from-to)709-715
Number of pages7
JournalBiotechnology and Bioprocess Engineering
Volume15
Issue number5
DOIs
StatePublished - 1 Oct 2010

Fingerprint

Antibodies
Half-Life
Therapeutics
Antibodies, Monoclonal, Humanized
Muromonab-CD3
Therapeutic Uses
Monoclonal antibodies
Serum
Immunoglobulins
Monoclonal Antibodies
Technology
Molecules
Pharmaceutical Preparations

Keywords

  • efficacy
  • immunogenicity
  • serum half-life
  • therapeutic monoclonal antibody

Cite this

Yoon, Soomin ; Kim, Yong Sung ; Shim, Hyunbo ; Chung, Junho. / Current perspectives on therapeutic antibodies. In: Biotechnology and Bioprocess Engineering. 2010 ; Vol. 15, No. 5. pp. 709-715.
@article{aed119d5de8640088cea8b10c1d62ad7,
title = "Current perspectives on therapeutic antibodies",
abstract = "Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2{\%} immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.",
keywords = "efficacy, immunogenicity, serum half-life, therapeutic monoclonal antibody",
author = "Soomin Yoon and Kim, {Yong Sung} and Hyunbo Shim and Junho Chung",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s12257-009-3113-1",
language = "English",
volume = "15",
pages = "709--715",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "5",

}

Current perspectives on therapeutic antibodies. / Yoon, Soomin; Kim, Yong Sung; Shim, Hyunbo; Chung, Junho.

In: Biotechnology and Bioprocess Engineering, Vol. 15, No. 5, 01.10.2010, p. 709-715.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Current perspectives on therapeutic antibodies

AU - Yoon, Soomin

AU - Kim, Yong Sung

AU - Shim, Hyunbo

AU - Chung, Junho

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.

AB - Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.

KW - efficacy

KW - immunogenicity

KW - serum half-life

KW - therapeutic monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=78649708348&partnerID=8YFLogxK

U2 - 10.1007/s12257-009-3113-1

DO - 10.1007/s12257-009-3113-1

M3 - Review article

VL - 15

SP - 709

EP - 715

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 5

ER -